Clin Lab. 2020 Dec 1;66(12). doi: 10.7754/Clin.Lab.2020.191229.
Multiple myeloma is a tumour of antibody-secreting plasma cells characterized by clonal expansion and accumulation of monotypic plasma cells in the bone marrow. It is an incurable malignant neoplasm accounting for 10% all hematological malignancies. Globally, the annual percentage of new cancer cases and deaths attributed to multiple myeloma is estimated at about 0.8% and 1%, respectively. Furthermore, its global incidence ranges from 0.5 - 12/100,000 population. It causes hypercalcemia, renal insufficiency, anemia, thrombocytopenia, leucopenia, bone lesions, bone fractures, spinal stenosis, and endorgan damages. This neoplasm occurs due to a complex cytogenetic and chromosomal aberrations. These aberrations affect the expression and functions of microRNAs. Abnormal expression of these microRNAs plays an important role in the pathogenesis and angiogenesis of multiple myeloma and could have a potential role in the diagnosis, prognostic stratification, and treatment of multiple myeloma. This review aimed at summarising the expression of microRNAs and the implication of their dysregulation in the pathogenesis, diagnosis, and treatment of multiple myeloma.
多发性骨髓瘤是一种由分泌抗体的浆细胞肿瘤,其特征是克隆性扩张和单克隆浆细胞在骨髓中的积累。它是一种不可治愈的恶性肿瘤,占所有血液系统恶性肿瘤的 10%。全球每年归因于多发性骨髓瘤的新癌症病例和死亡人数分别约为 0.8%和 1%。此外,其全球发病率范围为 0.5-12/100,000 人。它会导致高钙血症、肾功能不全、贫血、血小板减少、白细胞减少、骨病变、骨折、脊柱狭窄和终末器官损伤。这种肿瘤是由于复杂的细胞遗传学和染色体异常引起的。这些异常会影响 microRNAs 的表达和功能。这些 microRNAs 的异常表达在多发性骨髓瘤的发病机制和血管生成中起着重要作用,并可能在多发性骨髓瘤的诊断、预后分层和治疗中发挥作用。本综述旨在总结 microRNAs 的表达及其失调在多发性骨髓瘤发病机制、诊断和治疗中的意义。